首页> 外文期刊>Heart >The use of drug eluting stents in single and multivessel disease: results from a single centre experience
【24h】

The use of drug eluting stents in single and multivessel disease: results from a single centre experience

机译:药物洗脱支架在单支和多支血管疾病中的使用:单中心经验的结果

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: Drug eluting stents have been shown to reduce the rate of in-stent restenosis in cases where single lesions are treated. The performance of these stents, in patients with multivessel disease and complex lesions, however, remains unknown. Our experience with sirolimus eluting stents in such patients is presented. Design and patients: This study includes all consecutive patients treated at San Raffaele Hospital and EMO Centra Cuore Columbus, Milan, Italy treated with sirolimus eluting stents. Results: Between April 2002 and March 2003, 486 patients with 1027 lesions were treated (437 males, 49 females) with a mean (SD) age of 62.2 (10.5) years. Of all patients studied, 19.1% had single vessel disease, 33.8% had two vessel disease, and 47.1% had three vessel disease. Of the whole study group, 20.3% of patients had diabetes mellitus. A mean (SD) of 2.3 (0.4) stents per patient and 1.1 (0.2) stents per lesion were implanted. The baseline mean reference diameter was 2.7 (0.6) mm with a mean minimal luminal diameter of 0.9 (0.5) mm. Post-stenting, the acute gain was 1.8 (0.6) mm. During hospital stay one patient died (0.2%) and 13 (2.7%) patients had in-hospital myocardial infarction (Ml). One patient required urgent repeat percutaneous coronary intervention. Six months clinical follow up was performed in all 347 eligible patients. Six months mortality was 2.0% (n = 7) and acute Ml occurred in 0.3% (n = 1). Target lesion revascularisation occurred in 9.5% (n = 33) of the patients and target vessel revascularisation (TVR) in 11.5% (n = 40) of the patients. Major adverse cardiac event rate was 13.8% (n = 48). TVR was 4.5% for single vessel disease and 13.2% for multivessel disease. Diabetes mellitus was the only significant predictor for TVR. Conclusion: The use of drug eluting stents in single and multivessel coronary disease produces good short and medium term results with a low rate of revascularisation. Longer term follow-up is required to confirm these observations.
机译:目的:已证明药物洗脱支架可降低治疗单个病变的支架内再狭窄的发生率。然而,在多支血管疾病和复杂病变患者中,这些支架的性能仍然未知。介绍了我们在此类患者中使用西罗莫司洗脱支架的经验。设计和患者:本研究包括所有在San Raffaele医院和EMO Centra Cuore哥伦布(意大利米兰)接受西罗莫司洗脱支架治疗的连续患者。结果:2002年4月至2003年3月,共治疗486例1027例病灶(男437例,女49例),平均(SD)年龄为62.2(10.5)岁。在所有研究的患者中,有19.1%患有单支血管疾病,33.8%患有两支血管疾病,47.1%患有三支血管疾病。在整个研究组中,20.3%的患者患有糖尿病。每位患者平均植入2.3(0.4)个支架,每个病灶植入1.1(0.2)个支架。基线平均参考直径为2.7(0.6)mm,平均最小内腔直径为0.9(0.5)mm。支架置入后,急性增加为1.8(0.6)mm。在住院期间,一名患者死亡(0.2%),而13名患者(2.7%)患有院内心肌梗塞(M1)。一名患者需要紧急重复经皮冠状动脉介入治疗。对所有347名合格患者进行了六个月的临床随访。六个月的死亡率为2.0%(n = 7),急性M1发生率为0.3%(n = 1)。目标病灶血运重建发生在9.5%(n = 33)的患者中,目标血管血运重建(TVR)在11.5%(n = 40)的患者中。重大不良心脏事件发生率为13.8%(n = 48)。单支血管疾病的TVR为4.5%,多支血管疾病的TVR为13.2%。糖尿病是TVR的唯一重要预测因子。结论:在单支和多支冠状动脉疾病中使用药物洗脱支架可产生良好的短期和中期结果,血运重建率低。需要长期随访以确认这些观察结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号